Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TransCon hGH in Prepubertal Children With Growth Hormone Deficiency
NCT02781727Phase 3Completed
- Sponsor
- Ascendis Pharma
- Start
- Dec 2016
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Prodrugs/Conditional Activator Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of lonapegsomatropin in growth hormone deficiency (GHD) (2 arms), sponsored by Ascendis Pharma. Primary endpoint: Annualized Height Velocity at 52 weeks. Started Dec 2016; status: completed.
02
Drugs
lonapegsomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT02781727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02781727.